Neoprobe to Present at Stifel Nicolaus Healthcare Conference 2011
September 01 2011 - 10:07AM
Business Wire
Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer
of innovative oncology surgical and diagnostic products, today
announced that Dr. Mark Pykett, Neoprobe’s President and Chief
Executive Officer, will deliver a presentation to institutional
investors at 10:20 AM ET, Thursday, September 8, 2011 at the Stifel
Nicolaus Healthcare Conference 2011, taking place at The Four
Seasons Hotel, Boston.
Investors and the public are invited to listen to a live webcast
of Dr. Pykett’s presentation at
http://www.veracast.com/webcasts/stifel/healthcare2011/79205472.cfm.
An archived edition of the presentation will be available for 30
days following the presentation.
About Neoprobe
Neoprobe Corporation (NYSE Amex: NEOP) is a biomedical company
focused on enhancing oncology patient care and improving patient
benefit through radiopharmaceutical product development. Neoprobe
is actively developing two radiopharmaceutical agent platforms –
Lymphoseek® and RIGScanTM CR – to help surgeons better identify and
treat certain types of cancer. Neoprobe’s subsidiary, Cira
Biosciences, Inc., is also advancing a patient-specific cellular
therapy technology platform called ACT. Neoprobe’s strategy is to
deliver superior growth and shareholder return by bringing to
market novel radiopharmaceutical agents and advancing the Company’s
pipeline program through continued investment and selective
acquisitions. For more information, please visit
www.neoprobe.com.
Neoprobe Corp. Common Stock (AMEX:NEOP)
Historical Stock Chart
From May 2024 to Jun 2024
Neoprobe Corp. Common Stock (AMEX:NEOP)
Historical Stock Chart
From Jun 2023 to Jun 2024